Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Shelley Wood

September 22, 2022

News Conference News TCT 2021

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

Yael L. Maxwell

November 09, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

News Conference News TCT 2021

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

Michael O'Riordan

November 04, 2021

News Conference News TCT 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Yael L. Maxwell

October 22, 2021

News Conference News TCT 2020

Under ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care

Michael O'Riordan

October 19, 2020

News Conference News TCT 2020

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

Caitlin E. Cox

October 15, 2020

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

Todd Neale

October 14, 2020

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Todd Neale

September 30, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News TCT 2018

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

Michael O'Riordan

September 21, 2018

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Advertisement

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Good Early Outcomes With PCI in Complex Patients Unsuited to Surgery: OPTIMUM

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Under ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content